Login Register Cart 0
Generic placeholder image

Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1573-4064
ISSN (Online): 1875-6638

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis of N-Substituted Benzamide Derivatives and their Evaluation as Antitumor Agents

Author(s): Taiping Chen, Hongwu Jiang, Jianjun Zhou, Zicheng Li*, Wencai Huang, Youfu Luo and Yinglan Zhao

Volume 16, Issue 4, 2020

Page: [555 - 562] Pages: 8

DOI: 10.2174/1573406415666190712120611

Price: $65

Abstract

Background: Histone deacetylases inhibitors (HDACIs) with different chemical structures have been reported to play an important role in the treatment of cancer.

Objective: The study aims to modify the structure of Entinostat (MS-275) to discover new compounds with improved anti-proliferative activities and perform SAR studies on this class of bioactive compounds.

Methods: Fourteen N-substituted benzamide derivatives were synthesized and their antiproliferative activities were tested with four cancer cell lines (MCF-7, A549, K562 and MDA-MB- 231) by MTT assay.

Results: Compared with MS-275, six compounds exhibited comparable or even better antiproliferative activities against specific/certain cancer cell lines.

Conclusion: The preliminary SARs showed that (ⅰ) the 2-substituent of the phenyl ring in the R group and heteroatoms of amide which can chelate with zinc ion are critical to the antiproliferative activity and (ⅱ) chlorine atom or nitro-group on the same benzene ring largely decreases their anti-proliferative activity. Molecular docking study illustrated the interaction (binding affinity) between the synthesized compounds and HDAC2 was observed to be similar to that of MS-275.

Keywords: Anti-proliferative activity, cancer cell lines, MTT assay, molecular docking stimulation, N-substituted benzamide derivative, SAR studies.

« Previous Next »
Graphical Abstract

[1]
Venugopal, B.; Evans, T.R.J. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr. Med. Chem., 2011, 18(11), 1658-1671.
[http://dx.doi.org/10.2174/092986711795471284] [PMID: 21428881]
[2]
Kim, H.J.; Bae, S.C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res., 2011, 3(2), 166-179.
[PMID: 21416059]
[3]
Gao, S.; Zang, J.; Gao, Q.; Liang, X.; Ding, Q.; Li, X.; Xu, W.; Chou, C.J.; Zhang, Y. Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups. Bioorg. Med. Chem., 2017, 25(12), 2981-2994.
[http://dx.doi.org/10.1016/j.bmc.2017.03.036] [PMID: 28511906]
[4]
Ellis, L.; Pili, R. Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel), 2010, 3(8), 2411-2469.
[http://dx.doi.org/10.3390/ph3082441] [PMID: 21151768]
[5]
Petrella, A.; Fontanella, B.; Carratù, A.; Bizzarro, V.; Rodriquez, M.; Parente, L. Histone deacetylase inhibitors in the treatment of hematological malignancies. Mini Rev. Med. Chem., 2011, 11(6), 519-527.
[http://dx.doi.org/10.2174/138955711795843347] [PMID: 21561404]
[6]
Lu, H.; Chen, Y.D.; Yang, B.; You, Q.D. Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening. Acta Pharm. Sin. B, 2011, 1(4), 240-247.
[http://dx.doi.org/10.1016/j.apsb.2011.10.002]
[7]
Wang, H.; Dymock, B.W. New patented histone deacetylase inhibitors. Expert Opin. Ther. Pat., 2009, 19(12), 1727-1757.
[http://dx.doi.org/10.1517/13543770903393789] [PMID: 19939190]
[8]
Sonnemann, J.; Marx, C.; Becker, S.; Wittig, S.; Palani, C.D.; Krämer, O.H.; Beck, J.F. p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. Br. J. Cancer, 2014, 110(3), 656-667.
[http://dx.doi.org/10.1038/bjc.2013.742] [PMID: 24281001]
[9]
Mai, A.; Massa, S.; Rotili, D.; Simeoni, S.; Ragno, R.; Botta, G.; Nebbioso, A.; Miceli, M.; Altucci, L.; Brosch, G. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. [J]. J. Med. Chem., 2006, 49(20), 6046-6056.
[http://dx.doi.org/10.1021/jm0605536] [PMID: 17004718]
[10]
Zhang, X.; Lv, P.C.; Li, D.D.; Zhang, W.M.; Zhu, H.L. Navigating into the chemical space between MGCD0103 and SAHA: novel histone ceacetylase inhibitors as a promising lead. MedChemComm, 2015, 6(10), 1816-1825.
[http://dx.doi.org/10.1039/C5MD00247H]
[11]
Cai, J.; Zhang, Q.; Lin, K.; Hu, L.; Zheng, Y. The effect of MGCD0103 on CYP450 isoforms activity of rats by cocktail method. BioMed Res. Int., 2015, 2015(7), 517295
[http://dx.doi.org/10.1155/2015/517295] [PMID: 26357656]
[12]
Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko, Y.; Yamashita, T.; Nakanishi, O. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem., 1999, 42(15), 3001-3003.
[http://dx.doi.org/10.1021/jm980565u] [PMID: 10425110]
[13]
Irwin, J.J.; Raushel, F.M.; Shoichet, B.K. Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry, 2005, 44(37), 12316-12328.
[http://dx.doi.org/10.1021/bi050801k] [PMID: 16156645]
[14]
Babaoglu, K.; Simeonov, A.; Irwin, J.J.; Nelson, M.E.; Feng, B.; Thomas, C.J.; Cancian, L.; Costi, M.P.; Maltby, D.A.; Jadhav, A.; Inglese, J.; Austin, C.P.; Shoichet, B.K. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J. Med. Chem., 2008, 51(8), 2502-2511.
[http://dx.doi.org/10.1021/jm701500e] [PMID: 18333608]

Rights & Permissions Print Cite
Article Metrics
17
3
© 2024 Bentham Science Publishers | Privacy Policy